SCHEMBL7036015

SCHEMBL7036015

C/C=C\c1ccc(OCc2ccccc2)c(N)c1

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.49
LMNA P02545 1/20 0.49
APP P05067 7/20 0.46
AKR1C3 P42330 2/20 0.45
POLB P06746 1/20 0.45
UBE2N P61088 1/20 0.45
KMT2A Q03164 1/20 0.45
LCK P06239 1/20 0.44
RAB9A P51151 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
NPC1 O15118 1/20 0.44
NFKB1 P19838 1/20 0.44
NFKB2 Q00653 1/20 0.44
RELA Q04206 1/20 0.44
ALDH1A1 P00352 2/20 0.44
HPGD P15428 2/20 0.44
HTT P42858 1/20 0.44
LIPE Q05469 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7036016 1.00 KDM4E (0.49) KDM4ELMNAAPPAKR1C3POLB
SCHEMBL27396919 0.88 POLB (0.47) KDM4ELMNAAPPPOLBUBE2N
SCHEMBL7646409 0.84 FFAR4 (0.51) KDM4ELMNAAPPAKR1C3LCK
SCHEMBL7113088 0.84 FFAR4 (0.51) KDM4ELMNAAPPAKR1C3LCK
SCHEMBL3271115 0.82 APP (0.65) KDM4ELMNAAPPPOLBSMN1; SMN2
SCHEMBL14205236 0.82 KDM4E (0.52) KDM4ELMNAAPPAKR1C3RAB9A
SCHEMBL15963939 0.82 APP (0.58) KDM4ELMNAAPPPOLBSMN1; SMN2
SCHEMBL29529587 0.82 APP (0.65) KDM4ELMNAAPPPOLBSMN1; SMN2
SCHEMBL14763980 0.82 APP (0.65) KDM4ELMNAAPPPOLBSMN1; SMN2
SCHEMBL891624 0.82 APP (0.65) KDM4ELMNAAPPPOLBSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0659737-B1 Catecholamine surrogates useful as beta 3 agonists BRISTOL MYERS SQUIBB CO (US) 2003-03-26 EP disclosed
EP-0659737-A2 Catecholamine surrogates useful as B3 agonists BRISTOL-MYERS SQUIBB COMPANY (US) 1995-06-28 EP disclosed